[At-211] Parthanatine: Bringing Alphas to Tumor DNA Using a PARP-Targeted Therapeutic Radiopharmaceutical for Novel Indications
• Outlining At-211 labelled PARP-inhibitor analogs to target a binding site located on DNA
• Subcellar targeting to tumor DNA yield high potency alpha RPT
• Preclinical data support efficacy and tolerable toxicity in challenging disease such as neuroblastoma and ovarian cancer